- Home
- KINS vs MIST Comparison
KINS vs MIST Comparison
Compare KINS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | MIST |
|---|---|---|
| Founded | 1886 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 176.3M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KINS | MIST |
|---|---|---|
| Price | $15.15 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 87.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 359.65 | 51.80 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $155,142,103.00 | N/A |
| Revenue This Year | $40.63 | N/A |
| Revenue Next Year | $7.85 | N/A |
| P/E Ratio | $8.59 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $13.08 | $0.63 |
| 52 Week High | $22.20 | $3.06 |
Technical Indicators
Market Signals| Indicator | KINS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 50.25 |
| Support Level | $14.38 | $1.62 |
| Resistance Level | $15.51 | $1.79 |
| Average True Range (ATR) | 0.57 | 0.07 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 24.89 | 90.00 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).